

At Regeneron, we  
move science to  
medicine, because  
our world is

**MEANT  
FOR MORE**

**REGENERON®**



***PharmD***

**PROGRAM**

2027 - 2029

# CONTENTS



- 4** *About Regeneron*
- 5-12** *The PharmD Program*
  - 13** *The PharmD Program Alumni*
  - 14** *Applying to the PharmD Program*
  - 15-16** *Program Leadership*
  - 17** *Q&A*
  - 18** *Technology and Marketed Products*
  - 19** *Regeneron in Action*
  - 20** *Regeneron Approved and Investigational Medicines*
  - 21** *Leonard Schleifer, MD, PhD and  
George Yancopoulos, MD, PhD*
  - 22** *Select Honors and Recognitions*
  - 23** *About Our Location*



“

The Regeneron Way creates the perfect environment to turn ideas into action, make a meaningful impact on patients' lives, and accelerate one's professional growth.

”

**Zoya Sohail, PharmD**  
GRADUATE OF RUTGERS UNIVERSITY

# ABOUT REGENERON



Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

## THE REGENERON «««WAY»»»

### ➤ Lead With Science

Science drives our business and passion drives our science. Whether you're doing science, supporting science or delivering science. It's what we do.

### ➤ Take On Big Ideas

We take the long view and tackle the big ideas, the unsolvable problems, and the bottlenecks that get in the way. We pursue ideas with passion and courage, to make a real difference.

### ➤ Make It Happen

It may not always be easy, but we figure it out and get it done. We have little appetite for unnecessary bureaucracy that can get in the way of innovation or quality.

### ➤ Be Great Together

While others talk about teamwork, we actually do it. When you work with smart, fun people, you bring out the best in each other and can do the extraordinary.

### ➤ Do What's Right

We do well by doing good. We act with integrity and pride ourselves on doing the right thing - by each other, our communities, our patients and the world around us.

# THE PHARMD PROGRAM

The PharmD Program is an intensive, rotational, interdisciplinary program for PharmD or PhD professionals.

The objective for the PharmD Program is to provide training by Regeneron subject matter experts and hands-on experience in a variety of Global Development roles.

The PharmD Program is for highly motivated individuals seeking to build a career in the biopharmaceutical industry with a foundation in Development Operations & Program Management, Clinical Sciences, Regulatory Strategy, Regulatory Labeling and Advertising & Promotion, and/or Safety Sciences. 

## OBJECTIVES

PharmD Program Associates will:



**Gain knowledge of biopharmaceutical processes** in a variety of Global Development roles




Cultivate technical and non-technical skills through diverse **cross-functional experiences, ongoing mentorship, and targeted training**



Develop a balanced foundation of skills through **hands-on industry experience in functional areas**, including clinical development, regulatory affairs, and patient safety



Engage in **interdisciplinary professional development sessions** to maximize the learning and overall experience at Regeneron





## WHO IS THE IDEAL PHARMD PROGRAM CANDIDATE?

The ideal applicant is **intellectually curious, hard-working, and passionate** about science and continuous learning.

Qualified candidates are graduates of an accredited PharmD or PhD program. These individuals have a high academic standing preferably with some relevant experience. They have strong analytical, communication, and organizational skills and are adept at leadership and team roles.




Throughout the program, participants will cultivate technical and non-technical skills through diverse cross-functional experiences, ongoing mentorship, and targeted training.

Each assignment in this **2-year development program** will expose participants to critical issues and decision-making processes to gain broad experience across several clinical/scientific research areas.

The selected program participants will acquire high level knowledge of the business and department operations, as well as gain track-specific work experience.

# PROGRAM STRUCTURE OVERVIEW

24-months in one of these functional areas:



## FUNCTIONAL AREAS

# TRACK 1 DEVELOPMENT OPERATIONS & PROGRAM MANAGEMENT

In DO & PM, the Associate will focus on Clinical Trial Management and Program Management supporting and owning key activities across clinical trials and strategic programs in the Development Portfolio.



### Current First Year PharmD Associate

**MARY LALLY, PHD**  
Graduate of Rutgers University

Currently working in Development Operations and Program Management supporting the Immunology and Inflammation portfolio.

*"The PharmD Program has provided me with a unique opportunity to apply my scientific training and gain exposure to the many stages of clinical development. One of the most rewarding aspects has been seeing how scientific discoveries are translated into medicines that have the potential to make a meaningful difference for patients. I have been equally impressed by the willingness of colleagues across the organization to mentor, teach, and invest in the growth of associates. Through this combination of scientific rigor, collaboration, and mentorship, I have broadened my perspective on the biopharmaceutical industry and built a strong foundation for my career."*



### Current Second Year PharmD Associate

**SOPHIA SCHULTE, PHARM D**  
Graduate of the Medical College of Wisconsin School of Pharmacy

Currently working in Development Operations and Program Management supporting the Immunology and Inflammation portfolio.

*"The PharmD program offers a unique environment that challenges you, supports you, and prepares you for a successful career within the biopharmaceutical industry. This rotational based program offers an incredible opportunity to see both the scientific and operational sides of drug development. During my time, I've been given the chance to work on projects that truly impact patients, while learning from experts who are passionate about what they do."*

### In Clinical Trial Management, the Associate will:

- Perform key activities during the clinical trial start-up, maintenance, and close-out phases
- Contribute to program/study strategic feasibility and country and site selection
- Conduct site initiation visits (including presentations), site monitoring visits, and oversee patient enrollment planning
- Review clinical study budgets and timelines, and interact cross-functionally with various internal team members and external clinical sites and vendors


### In Program Management, the Associate will:

- Work on a cross-functional program development team and contribute to development of strategic plans
- Integrate drug development planning and execution from early development through BLA submission
- Develop and manage integrated program budgets, timelines, and project plans, including scenario planning and risk mitigation
- Participate in and facilitate governance meetings, including the Global Clinical Sub-Team, Strategic Program Team, Development Program Reviews, and Integrated Program Financial Reviews

## FUNCTIONAL AREAS

# TRACK 2 CLINICAL SCIENCES

In Clinical Sciences, the Associate will participate in activities throughout the lifetime of a drug development program from supporting the development of pre-IND/IND documents through regulatory submissions. The Clinical Scientist Associate will play an instrumental role through all phases of clinical development to bring life-changing medicines to patients. Studies supported may include translational research, clinical experimental sciences, early/late phase clinical trials, and post-marketing requirements.



### Current First Year PharmD Associate

**KATELYN GILLIES, PHARM D**  
Graduate of Rutgers University

Currently working in Clinical Sciences supporting studies in the Genetic Medicines portfolio.

*"Regeneron is a science-driven company that empowers Associates to learn, contribute, and grow. With the support of passionate colleagues and exceptional mentors, I have been able to make meaningful contributions to clinical trial design within the Genetic Medicines portfolio. The Clinical Sciences track provides valuable opportunities to build the skills, knowledge, and confidence needed for a successful career as a Clinical Scientist."*



### Current Second Year PharmD Associate

**JANE WITKIN, PHARM D**  
Graduate of Rutgers University

Currently working in Clinical Sciences supporting studies in the Hematology and Genetic Medicine portfolios.

*"As a Clinical Sciences Associate, you'll gain hands-on expertise across Regeneron's diverse portfolio, spanning first-in-human to late-stage studies, all while learning from great leaders. The program's rotational structure and mentorship provide an unparalleled foundation for a successful career in the industry."*

### In Clinical Sciences, the Associate will:

- Participate in medical monitoring through the review of site clinical data and raising of medical queries
- Contribute to the development of clinical study designs and protocol writing
- Develop key documents such as expanded synopses, protocol amendments, investigator brochures, safety reports, and monitoring plans
- Design case report forms for studies and participate in user acceptance testing for databases
- Participate in and facilitate key meetings with sites such as those regarding dose escalation decisions
- Train internal team members and site on study protocol
- Become familiar with regulatory agency guidance for study design of relevant trial phases, therapeutic areas, and drug technology

## TRACK 3 REGULATORY STRATEGY

In Regulatory Strategy, the Associate will support and provide project management for the operations governing pharmaceutical drug development to all aspects of Regeneron's quality, preclinical and clinical drug development programs, policies, and procedures meeting the necessary state of compliance relative to all regulatory commitments.



**Current First Year PharmD Associate**

**DELANEY LACEY, PHD**  
Graduate of Princeton University

Currently working in Regulatory Program Management supporting the Oncology portfolio.

*"What sets Regeneron apart is their dedication to science and doing good. As an Associate, I learn from experienced mentors and work with cross-functional teams to get innovative medicines to patients. The skills gained from this program provide a solid foundation for your career as a regulatory strategist. It is incredibly rewarding to grow and work alongside smart, capable people who are always willing to help, who are not afraid to get creative, and who want to tackle the tough problems to better the lives of patients."*



**Current Second Year PharmD Associate**

**DOUGLAS OBERNADER, PHARM D**  
Graduate of the University of Michigan

Currently working in Regulatory Strategy supporting the General Medicine portfolio.

*"As a PharmD Associate at Regeneron, I have had the unique opportunity to immerse myself in the biopharmaceutical industry while deepening my understanding of regulatory strategy and related functions. The company's science-first mindset drives meaningful innovation, and through hands-on training and collaboration, I've been able to make a positive impact on multiple programs. The supportive community, continual mentorship, and dynamic projects have truly allowed me to grow both professionally and personally, all while advancing medicine for patients."*

### In Regulatory Strategy, the Associate will:

- Participate in the development of regulatory strategies in collaboration with the development teams by conducting research and review of guidelines, regulatory precedence, and competitive intelligence
- Assist in managing the timelines, preparation, compilation, review, organization, and submission of regulatory deliverables including INDs, CTAs, BLAs, IND amendments, and BLA supplements in accordance with Title 21 CFR and all FDA and ICH guidelines
- Support the drafting and review of regulatory documents, including briefing materials and labeling documents
- Manage overall completeness of scheduled submissions and coordinate with Regulatory Operations on submission timing and document status
- Participate in cross-functional departmental team projects and product development activities/meetings

## TRACK 4 REGULATORY LABELING AND ADVERTISING & PROMOTION

In Regulatory Labeling and Advertising & Promotion, the Associate will gain knowledge on the role of Labeling throughout a drug's lifecycle, learn about the role of Ad Promo in the commercialization of drug products, and collaborate cross functionally with key stakeholders.



**Current First Year PharmD Associate**  
**STEPHANIE APPIAH, PHARM D**  
Graduate of Binghamton University

Currently working in Regulatory Labeling Strategy supporting the Rare Disease portfolios.

*"Being an Associate in the PharmD program at Regeneron means stepping directly into impactful work, navigating cross-functional teams, and building high-level expertise across key areas of development. At Regeneron, scientific innovation is truly the driving force behind every breakthrough. The culture uniquely balances hands-on accountability with dedicated guidance from leaders who are deeply invested in your growth as a biopharmaceutical industry professional. It's an empowering environment where your daily efforts contribute to the shared mission of doing what's right for patients."*



**Current Second Year PharmD Associate**  
**TEMILOLUWA AWOLEYE, PHARM D**  
Graduate of Texas Southern University

Currently working in Regulatory Advertising & Promotion supporting the Hematology portfolio.

*"Science to medicine" isn't just a saying here at Regeneron—it's our guiding principle and the litmus test for every discovery we pursue. Our mission is fueled by a deep dedication to the patients we are called to serve, and by a commitment to transforming groundbreaking scientific discoveries into medicines that impact patients' lives. For future candidates exploring the program, know that this is a place where innovation, collaboration, and purpose come together. Here, Associates are more than just a participant—we are valued members of the team, and our contributions truly matter."*

### In Regulatory Labeling Strategy, the Associate will:

- Contribute to the development of healthcare provider (HCP) and patient labeling documents for regulatory submissions, including participating in Labeling Working Groups and obtaining management approval of labeling documents
- Manage the Labeling process throughout the product life cycle, prepare submission-ready labeling documents and support preparation of responses to Health Authorities during labeling negotiations
- Contribute to the development of labeling strategies through interpretation of regulations and guidelines

### In Advertising & Promotion, the Associate will:

- Develop knowledge and skills to interpret FDA regulations and guidances to ensure promotional communication for HCPs and consumers is truthful and not misleading, and appropriately advise teams on associated regulatory risks
- Assist in FDA - Office of Prescription Drug Promotion (OPDP) interactions for assigned company products and maintain effective working relationship with FDA OPDP reviewers
- Monitor the external environment on evolving regulatory landscape related to product and disease state communications to strategically advise internal product and cross-functional teams

## FUNCTIONAL AREAS

# TRACK 5 SAFETY SCIENCES

In Safety Sciences, the Associate will gain a working knowledge of various disciplines that enable the continuous assessment of the benefit-risk of Regeneron products throughout their lifecycle, from early clinical development through market authorization and postmarketing surveillance, with a focus on signal detection and management. This includes gaining an understanding of safety data collection, evaluation, and reporting, establishing the framework for signal detection and management activities. There will be close collaboration with other disciplines within Global Development to provide a well-rounded perspective on how safety contributes to successful drug development and ensures safe use of Regeneron's products.



**Current First Year PharmD Associate**  
**NICHOLAS GLAZEWSKI, PHARM D**  
Graduate of Rutgers University

Currently working in Safety Sciences supporting the Hematology/Oncology portfolio.

*"The PharmD Program has allowed me to expand upon my clinical training while gaining firsthand experience in the development of new therapies. Through the Safety Sciences track, I have been able to learn from experienced colleagues, collaborate with cross-functional teams, and contribute to work that supports patient safety throughout the development process. The combination of mentorship, professional development, and meaningful responsibilities has made this a rewarding experience and an outstanding way to begin a career in the biopharmaceutical industry."*



**Current Second Year PharmD Associate**  
**ZOYA SOHAIL, PHARM D**  
Graduate of Rutgers University

Currently working in Safety Sciences supporting the General Medicine portfolio.

*"The PharmD Program provides an exceptional opportunity to build upon clinical education with specialized training in drug development across diverse functional areas. Associates acquire in-depth experience within their chosen track, and also are able to benefit from exposure to related functional areas and the interplay between them. Regeneron's science-driven and patient centered culture creates an immersive and rewarding environment, empowering Associates to launch fruitful careers in the biopharmaceutical industry."*

### In Safety Sciences, the Associate will:

- Understand Individual Case Safety Report (ICSR) data collection, evaluation, and reporting, including a working knowledge of safety database and tools
- Support preparation of aggregate safety reports for development and marketed products
- Understand functional areas within Pharmacovigilance (PV) Operations, including quality & compliance, standards & training, PV partnerships, and agreements & licensing
- Gain an understanding of how pharmacoepidemiology data plays a key role in the overall safety assessment through participation in the planning and execution of a pharmacoepidemiology project
- Participate and support signal detection activities, including data review, signal evaluation report preparation, drafting risk management plans, response to regulatory inquiries, and preparation of other safety submissions
- Organize, support, and participate in Safety Management Team (SMT) meetings

# HOW HAS YOUR EXPERIENCE IN THE REGENERON PHARM D PROGRAM PREPARED YOU FOR YOUR ROLES?



*"Regeneron is a company that is driven by people who are passionate about patient-centric innovation. The PharmD Program grants Associates with a unique opportunity to collaborate across a variety of functions and therapeutic areas. The program's focus on cutting-edge science and mentorship empowers Associates to develop valuable skills and make meaningful contributions to the development of potentially life-changing medications."*

## **ALLISON NGUYEN, PHARM D**

**Manager, Regulatory Affairs**

Former Regulatory Strategy PharmD Associate (2024-2026)




*"From first-in-human studies to late-stage trials, the Clinical Sciences track offers hands-on experience across Regeneron's diverse pipeline—with opportunities to support innovative modalities and diverse indications—all guided by dedicated mentorship. The broad experiences in this program will help you discover your interests while equipping you with the skills to shape your career as a clinical scientist."*

## **SLADE SCHNEIDER, PHARM D**

**Manager, Clinical Sciences**

Former Clinical Sciences PharmD Associate (2024-2026)



*"The PharmD Program provided foundational training that allowed me to integrate seamlessly into development teams and contribute meaningfully to drug development. This training, paired with strong mentorship, was pivotal in preparing me for the role I'm in today."*

## **ANDRE RICKARD, PHARM D**

**Manager, Global Patient Safety**

Former Safety Sciences PharmD Associate (2024-2026)



*"This Program provided me with invaluable hands-on experience paired with robust mentorship and guidance, including from Senior Leadership, facilitating a seamless transition into my current role. The breadth and depth of my day-to-day responsibilities allowed me to both build technical expertise and refine my regulatory judgment. Additionally, I benefitted from an extensive network of current Associates and Alumni, a resource that continues to strengthen the Program's impact and support long after each cohort completes it."*

## **RIYA VINOY, PHARM D**

**Manager, Regulatory Affairs Advertising & Promotion**

Former Regulatory Labeling and Advertising & Promotion PharmD Associate (2024-2026)

# APPLYING TO THE PHARMD PROGRAM



## APPLY AT CAREERS.REGENERON.COM AND SEARCH THE PHARMD PROGRAM



Application must **include CV and cover letter** submitted for track of interest



Application deadline: **September 11<sup>TH</sup>**



Final interviews will be conducted **on-site**



IF YOU HAVE QUESTIONS,  
PLEASE CONTACT US AT

**pharmdbp@regeneron.com**

APPLICATION OPENS AT  
**CAREERS.REGENERON.COM**  
ON AUGUST 24<sup>TH</sup>



ONLINE APPLICATION  
PORTAL CLOSSES  
SEPTEMBER 11<sup>TH</sup>



INTERVIEWS WILL BE SCHEDULED  
WITH CANDIDATES DIRECTLY  
ONCE THE APPLICATION CLOSSES



RECOMMENDATIONS ARE NOT  
REQUIRED TO BE SUBMITTED  
AS PART OF THE INITIAL  
APPLICATION. REFERENCES  
WILL BE COLLECTED AFTER  
FINAL OFFERS ARE EXTENDED.

# PROGRAM LEADERSHIP

## EXECUTIVE PROGRAM SPONSORS



**BARI KOWAL**  
Senior Vice President

Head Development Operations,  
Portfolio Management &  
Biostatistics Data Management



**MARY ALICE RAUDENBUSH**  
Vice President

CMC Regulatory Affairs

## PROGRAM ADVISORS AND MENTORS

The program advisors are available to help navigate your experience, help you connect with resources within the company, and provide feedback to support your continued growth at Regeneron.



*"I'm excited to be a program mentor where numerous opportunities exist for graduates to explore several departments. Our 'science first' culture at Regeneron, which fosters curiosity, collaboration, and exploration, is embedded into the program, giving us opportunities to continually learn and grow at the company."*

**MIRIAM KORE, PHARM D**  
Executive Director, Clinical Development Unit Operations Leader



*"The PharmD Program is a two-way avenue, where PharmD and PhD graduates have a unique opportunity to learn and contribute to the cutting-edge science and drug development that is performed across several departments, and at the same time it allows Regeneron Associates to advance their people managing and mentoring skills."*

**OLIVIER HARARI, MD**  
Vice President, Genetic Medicines Clinical Development



*"As a former PharmD post-doctoral program graduate, I am delighted to be involved in the direct mentorship of future pharmaceutical leaders. We will work to seamlessly integrate our Associates into exciting programs to enable their continued growth, independence and competency as they strive to help the company reach program goals."*

**DONATO FORLENZA, PHARM D**  
Executive Director, Regulatory Affairs

## PROGRAM ADVISORS AND MENTORS



*"It is truly energizing to work at Regeneron where you are surrounded by exceptionally talented individuals in a highly collaborative environment, all working together to progress great science and improve patient lives. Our PharmD Associates have a unique opportunity to not only learn through observing and shadowing, but also to actually manage projects on their own within a short time frame and feel the impact of their contributions, as they learn. It is extremely rewarding to be a part of such a program."*

**PEARL RAWSON, PHARM D**

**Executive Director, Regulatory Labeling and Advertising & Promotion**



*"The PharmD Program provides the opportunity for PharmD and PhD graduates to get the best-in-class training at one of the most scientifically-minded biotech organizations. Regeneron is deeply rooted in its belief of "doing well by doing good", reflected in every aspect of our work. There's wide recognition that our people are our most important asset, and developing talent from within enables our mission of advancement in science and ultimately benefiting patients. I am very proud to be part of this important program!"*

**STEPHANIE BIEDERMANN**

**Senior Director, Development Program Management**



*"The PharmD Program provides a unique opportunity for PharmD and PhD graduates to gain valuable industry experience as integral team members in a global matrixed environment. The program offers foundational, hands-on experience working on meaningful assignments independently and cross-functionally, with access to resources, tools, and technology. Regeneron's program connects the PharmD's clinical education with broader applications in the pharmaceutical industry setting, positioning pharmacists to understand their impact on regulatory, safety, and operational aspects. I am proud to represent Global Patient Safety as a board member for this rewarding program and support the next generation of aspiring industry leaders."*

**NICOLE PERNA, PHARM D**

**Director, Global Patient Safety**

# Q&A

1

## WHAT IS THE DIFFERENCE BETWEEN A FELLOWSHIP AND OUR PHARMD PROGRAM?

Our program has **no university affiliation**, allowing for complete attention towards your professional development and engagement in the Regeneron community. Associates of the program are **full-time employees** of Regeneron and are given the opportunity to be fully contributing members of the team. Members of the program experience full company benefits while being able to thrive in an active learning environment.

2

### DO YOU CHOOSE YOUR THERAPEUTIC AREA OR IS IT ASSIGNED TO YOU?

Designation of therapeutic area is decided based on a combination of personal interests, business need, and availability of team members to mentor new Associates.

3

### WHEN WILL WE HEAR BACK AFTER WE SUBMIT OUR APPLICATION?

Applicants should submit their materials by September 11<sup>TH</sup> for consideration. Applicants will be contacted after the submission deadline regarding interviews.

4

### TO WHOM SHOULD THE COVER LETTER AND OTHER APPLICATION REQUIREMENTS BE ADDRESSED?

Please address your letter of intent to:

**Applicant Reviewers**

**The PharmD Program | Regeneron Pharmaceuticals  
777 Old Saw Mill River Rd, Tarrytown, NY 10591**

# TECHNOLOGY AND MARKETED PRODUCTS

Our core capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, these technologies represent some of the most valuable biotechnologies ever created, and aid our efforts to continuously accelerate the average timeline from discovery to drug approval – ultimately allowing us to help more patients around the world, faster. We will continue to raise the bar for R&D excellence and productivity in the biotech industry.

## 15 REGENERON-INVENTED MEDICINES

**Arcalyst**<sup>1</sup>  
(rilonacept)

**DUPIXENT**<sup>2</sup>  
(dupilumab) Injection

**Evkeeza**<sup>3</sup>  
(evinacumab-dgnb)

**EYLEA**<sup>4</sup>  
(aflibercept) Injection

**EYLEA HD**<sup>4</sup>  
(aflibercept) Injection 0.3 mg

**Inmazeb**<sup>5</sup>  
(atoltivimab, maffivimab,  
and odesivimab - ebgm)  
Injection  
16.67 mg/16.67 mg/16.67 mg per mL

**KEVZARA**<sup>5</sup>  
(sarilumab)  
Please see full Prescribing  
Information including Boxed  
WARNING for KEVZARA.

**LIBTAYO**<sup>6</sup>  
(cemiplimab-rwlc)

**LYNOSYFIC**<sup>7</sup>  
(linvoseltamab-gcpt)  
Please see full Prescribing  
Information including Boxed  
WARNING for Lynosyfic.

**Praluent**<sup>6</sup>  
(alirocicab) Injection

**Veopoz**<sup>5</sup>  
(pozelimab-bbfg)  
Injection  
Please see full Prescribing  
Information including Boxed  
WARNING for Veopoz.

**ZALTRAP**<sup>5</sup>  
(ziv-aflibercept)

**Ordspono**<sup>8</sup>  
(odronextamab)

**REGEN-COV**<sup>7</sup>  
(casirivimab and imdevimab)

**Otarmeni**<sup>9</sup>  
(lunsotogene parvec-cvha)  
suspension, for intravitreal injection

1. Commercialized by Kiniksa Pharmaceuticals, Ltd.
2. Commercialized with Sanofi.
3. Commercialized by Regeneron in the United States and Ultragenyx Pharmaceuticals Inc. outside the United States
4. Commercialized by Regeneron in the United States and Bayer outside the United States

5. Commercialized by Sanofi
6. Commercialized by Regeneron in the United States and Sanofi outside the United States
7. No longer authorized for use in the U.S. and other regions

# REGENERON IN ACTION – WHERE WE ARE TODAY

After 35+ years of scientific leadership, we continue to push the bounds of science to bring new medicines to patients

## OUR SCIENCE & MEDICINES

**15** 

medicines approved in the U.S.  
and/or other countries

**Nearly 50** 

product candidates in clinical development  
across multiple therapeutic areas

**50+** 

countries with clinical trials

**3M+** 

exomes sequenced to date  
by the Regeneron Genetics Center®

## OUR COMPANY

**15.4K+** 

Regeneron employees worldwide

**Top 5** 

ranking as a *Science* Top Employer for  
fourteen consecutive years

**\$5.9B** 

R&D investment in 2025

**35+** 

Years of scientific leadership

## OUR RESPONSIBILITY

**Top 10%** 

ranking in biotech industry  
across 3 leading ESG ratings

**4M+** 

students reached by Regeneron  
STEM initiatives since 2020

**50%** 

employee volunteerism rate in 2025

**6** 

consecutive years on the Dow Jones  
Sustainability Index (DJSI)

Last updated: May 2026

# REGENERON APPROVED AND INVESTIGATIONAL MEDICINES ACROSS A DIVERSE SET OF DISEASES

| Phase 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Phase 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | FDA-Approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>REGN5837</b> (CD22xCD28)<br/> <b>REGN7945</b> (CD38xCD28)<br/> <b>REGN17372</b> (GPC5DxCD28)</p> <p><b>REGN4336</b> (PSMAxCD3)<br/> <b>27T51</b> (MUC16 CAR-T)<br/> <b>REGN10597</b> (PD-1-IL2Ra-IL2)</p> <p><b>ALN-PNP*</b> (PNPLA3)<br/> <b>ALN-APOC3*</b> (APOC3)<br/> <b>REGV131-LNP1265*</b> (Factor 9)<br/> <b>ALN-CIDEB*</b> (CIDEB)<br/> <b>ALN-CFB*</b> (CFB)<br/> <b>REGN9533</b> (Factor XII)<br/> <b>ALN-F1202*</b> (Factor XII)<br/> <b>REGN13335</b> (PDGFβ)</p> <p><b>vonsetamig</b> (BCMAxCD3)</p> <p><b>ALN-SOD*</b> (SOD1)<br/> <b>ALN-HTT02*</b> (HTT)<br/> <b>ALN-SNCA*</b> (Synuclein)<br/> <b>ALN-5288*</b> (MAPT)<br/> <b>TSRA-196**</b> (SERPINA1)</p> | <p><b>ubamatamab</b> (MUC16xCD3)<br/> <b>nezastomig</b> (PSMAxCD28)<br/> <b>marlotamig</b> (EGFRxCD28)<br/> <b>davutamig</b> (METxMET)<br/> <b>REGN5668</b> (MUC16xCD28)</p> <p><b>rapirosiran†</b> (HSD17B13)<br/> <b>trevogrumab</b> (GDF8)<br/> <b>REGN7544</b> (NPR1 antagonist)<br/> <b>ALN-ANG3†</b> (ANGPTL3)<br/> <b>olatorepatide††</b> (GLP-1/GIP)</p> <p><b>sarilumab*</b> (IL-6R)</p> <p><b>Lunsotogene parvec</b> (Otoferlin Gene Therapy)<br/> <b>REGN7999</b> (TMPRSS6)</p> | <p><b>odronextamab</b> (CD20xCD3)<br/> <b>linvoseltamab</b> (BCMAxCD3)</p> <p><b>cemiplimab</b> (PD-1)<br/> <b>fianlimab</b> (LAG-3)</p> <p><b>REGN7508</b> (Factor XI)<br/> <b>REGN9933</b> (Factor XI)</p> <p><b>dupilumab*</b> (IL-4R)<br/> <b>itepekimab*</b> (IL-33)<br/> <b>REGN5713-5715</b> (Bet v 1)<br/> <b>REGN1908-1909</b> (Fel d 1)</p> <p><b>garetosmab</b> (Activin A)<br/> <b>cemdisiran ± pozelimab†</b> (C5 siRNA ± anti-C5)<br/> <b>mibavademab</b> (LEPR)<br/> <b>nexiguran ziclumeran#</b> (TTR)</p> | <p><b>Arcalyst†</b> (rilonacept)<br/> <small>Injection for Subcutaneous Use</small></p> <p><b>EYLEA®</b> (aflibercept) Injection<br/> <small>For Intravitreal Injection</small></p> <p><b>ZALTRAP\$</b> (ziv-aflibercept)<br/> <small>Injection for Intravenous Infusion</small></p> <p><b>DUPIXENT*</b> (dupilumab)</p> <p><b>LIBTAYO*</b> (cemiplimab-rwc)<br/> <small>Injection 300 mg</small></p> <p><b>Evkeeza**</b> (avincumab-dgnb)<br/> <small>Injection</small></p> <p><b>Veopoz</b> (pozelimab-bbtg)<br/> <small>Injection</small></p> <p><b>Otarmeni™</b> (lunsotogene parvec-cwha)<br/> <small>suspension, for intracochlear infusion</small></p> <p><b>EYLEA HD®</b> (aflibercept) Injection 2 mg<br/> <small>For Intravitreal Injection</small></p> <p><b>Praluent®</b> (olirocumab) Injection 200mg/mL</p> <p><b>KEVZARA*</b> (sarilumab)</p> <p><b>Inmazeb®</b> (atozivimab, mofvizimab, and odesivimab - ebgm)<br/> <small>Injection</small></p> <p><b>LYNOZYFIC®</b> (linvoseltamab-gcpt)</p> |
| <p> <span>HEME-ONC</span> <span>SOLID TUMOR ONCOLOGY</span> <span>CARDIOMETABOLIC / INTERNAL MEDICINE</span> <span>I&amp;I</span> <span>OPHTHALMOLOGY</span> <span>NEUROLOGY / RARE DISEASE</span> <span>Approx. 50 product candidates</span> </p>                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Agreement with: \*Sanofi; †Alnylam; ‡Intellia; \*Bayer; \*\*Ultragenyx; ††Hansoh; ‡‡Tessera; \*Kiniksa is solely responsible for development and commercialization of ARCALYST; ‡Sanofi is solely responsible for development and commercialization of ZALTRAP.

As of April 2026; ALN-SOD is on U.S. FDA clinical hold, enrolling ex-U.S. All trademarks mentioned are the property of their respective owners.

This slide contains investigational drug candidates that have not been approved by any regulatory authority.

# REGENERON

Regeneron has become one of the great science-driven companies of our generation, with numerous approved treatments, a nearly entirely homegrown pipeline and the best technologies in the business. We got here by following the science and trusting our people. But at Regeneron, we're never done. Our goal is to continue pushing the boundaries of science, to the extent that we aren't even able to imagine the breakthroughs and cures we will be known for in ten or twenty years. It's an incredible time to be at Regeneron, as we stand on the edge of an unprecedented future.

**GEORGE D. YANCOPOULOS, MD, PHD**  
co-Founder, Board co-Chair, President and Chief Scientific Officer





## SELECT HONORS AND RECOGNITIONS

**S&P Global**

Dow Jones Sustainability  
World Index

Dow Jones Sustainability  
North America Index



Most Community Minded  
Companies in the Nation

**Science**  
AAAS

Top Employers

**LinkedIn**

LinkedIn Top Companies

**PV PharmaVoice**

PharmaVoice 100 Top  
Industry Leaders



Pharmaceutical  
Invention Index

**Newsweek**

America's Most  
Responsible Companies

**Forbes**

America's Best  
Employers for Women



Corporate Equity Index

**BioSpace**

Best Places to Work



PRIX GALIEN USA

Prix Galien USA Best Biotechnology  
Product (2025)



# ABOUT OUR LOCATION

The PharmD Program is located primarily in Tarrytown, NY. Tarrytown is located along the eastern bank of the Hudson River, about 25 miles north of midtown Manhattan.

For over 35 years, the Westchester County community has helped us grow. Because of that, we've been actively expanding our existing 1.7 million square feet of state-of-the-art laboratory resources that employ more than 4,000 passionate employees across the region who all have the same mission—advancing the delivery of life-changing medicines for the growing number of patients in need.



*Put the world at your doorstep. With our region's reliable interconnected roadways, bus stations, rail lines and leading regional airport, traveling around the world is as convenient as traveling around our county.*



*Feel safe and secure. Our highly ranked, safe neighborhoods are home to some of the nation's leading healthcare systems, so you can ensure you have the resources you need –around the block.*



*Set up success. Westchester's strong school districts, top graduation rates and several colleges and universities provide opportunity for the success of you and your family.*



*Enjoy your weekdays and your weekends. Westchester has an abundance of restaurants, performing-arts venues, sports centers, special events, and night life that make it easy to fill your weekend but difficult to choose how.*

**REGENERON**  
SCIENCE TO MEDICINE™

*CREATE THE FUTURE  
YOU BELIEVE IN*



IF YOU HAVE QUESTIONS,  
PLEASE CONTACT US AT

**[pharmdbp@regeneron.com](mailto:pharmdbp@regeneron.com)**